Join to view full profile
3838 N Campbell Ave Unit 10Tucson, AZ 85719
Phone+1 314-853-1185
Dr. Shroff is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Rachna Shroff is an oncologist based in Tucson, AZ, who specializes in gastrointestinal cancer. She completed her medical education at Sidney Kimmel Medical College, followed by a residency in internal medicine at the Washington University/B-JH/SLCH Consortium and a fellowship in hematology and medical oncology at the University of Texas Health Science Center at Houston/MD Anderson Cancer Center. Her research focuses on hepatocellular carcinoma, cholangiocarcinoma, pancreatic cancer, biliary tract cancer, and gallbladder adenocarcinoma. Dr. Shroff has contributed numerous publications to the field, including a randomized trial on biliary tract cancers and studies on pancreatic cancer subtypes. She has also been involved in clinical trials, serving as a principal investigator in studies such as the Atezolizumab + Cabozantinib trial for metastatic pancreatic cancer.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2004 - 2007
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2004
Certifications & Licensure
AZ State Medical License 2018 - 2027
TX State Medical License 2007 - 2024
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015
Clinical Trials
- Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer Start of enrollment: 2021 Oct 12
Roles: Principal Investigator, Contact
- Immune Response to the COVID-19 Vaccine Start of enrollment: 2021 Jun 07
- Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) Start of enrollment: 2020 Jun 23
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Genomic analysis of oesophageal carcinoma (EC) identifies recurrent mutations in histone methyltransferases as a distinctive subset.Jingyuan Wang, Joanne Xiu, Francesca Battaglin, Hiroyuki Arai, Shivani Soni
Oncogene. 2026-09-01 - Radiation Therapy for Pancreatic Cancer: An ASTRO Clinical Practice Guideline.Michael D Chuong, Krishan R Jethwa, Ethan Ludmir, Amol Narang, Marsha Reyngold
Practical Radiation Oncology. 2026-08-11 - 1 citationsElraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial.Devalingam Mahalingam, Rachna T Shroff, Benedito A Carneiro, Yan Ji, Andrew L Coveler
Nature Medicine. 2026-05-01
Press Mentions
Practice-Changing Results Reported for Revolution Medicines Pancreatic Cancer DrugMay 31st, 2026- Experimental Pill Promises New Hope for Deadly Pancreatic CancerMay 31st, 2026
- HER2-Positive Gastroesophageal Cancer: Zanidatamab plus Chemotherapy Prolongs Progression-Free SurvivalJanuary 6th, 2026
Grant Support
- Establishing the University of Arizona Cancer Center as a Lead Academic Participating Site in the National Clinical Trials NetworkUNIVERSITY OF ARIZONA2026–2032
- Enhancing NCI-funded research at the University of Arizona Cancer CenterUNIVERSITY OF ARIZONA2025–2030
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
